Loading...
•
Dec 31, 2022
Rigel Q4 2022 Earnings Report
Rigel reported financial results, including TAVALISSE® and REZLIDHIA™ sales, and total revenues of $51.3 million.
Key Takeaways
Rigel reported a net income of $1.4 million for the fourth quarter of 2022, with total revenues of $51.3 million, including sales of TAVALISSE® and REZLIDHIA™.
Rigel reported net income of $1.4 million, or $0.01 per basic and diluted share, compared to a net loss of $22.6 million for the same period of 2021.
Total revenues were $51.3 million, including $21.9 million in TAVALISSE net product sales and $0.9 million in REZLIDHIA net product sales.
TAVALISSE net product sales increased by 25% to $21.9 million from $17.6 million in the fourth quarter of 2021.
Total costs and expenses were $49.2 million, compared to $41.8 million for the same period of 2021.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...